keyword
MENU ▼
Read by QxMD icon Read
search

NSLCL

keyword
https://www.readbyqxmd.com/read/29663359/lncrna-dgcr5-contributes-to-csc-like-properties-via-modulating-mir-330-5p-cd44-in-nsclc
#1
Ren Wang, Hui-Xing Dong, Jian Zeng, Jing Pan, Xiao-Yan Jin
Non-coding RNAs can exert significant roles various cancers, including NSCLC. Previously, we indicated that lncRNA DGCR5 can promote lung cancer progression through inhibiting hsa-mir-22-3p. In our current study, we investigated the role of DGCR5 in cancer stem cell-like properties of NSCLC. CSCs have been recognized as the frequent cause of tumor metastasis, tumor recurrence, and chemotherapy resistance. Here, lung cancer stem cells were successfully enriched from the parental NSCLC A549, H460, and H1299 cells by using tumor sphere formation assays and side population (SP) assays...
April 16, 2018: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/28390118/erlotinib-associated-rash-in-advanced-non-small-cell-lung-cancer-relation-to-clinicopathological-characteristics-treatment-response-and-survival
#2
Ilias Kainis, Nikolaos Syrigos, Alexandra Kopitopoulou, Ioannis Gkiozos, Effrosyni Filiou, Vasiliki Nikolaou, Evangelia Papadavid
Systematic treatment of advanced non-small cell lung cancer (NSCLC) includes targeted treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The development of skin rash and its intensity have been associated with EGFR TKI's efficacy. The main purpose of this study was to further investigate the potential value of erlotinib-associated rash as a predictor of prognosis and treatment response in a real-world cohort of patients with advanced NSCLC. The medical records of all NSCLC patients treated with erlotinib at the Oncology Unit of GPP, Sotiria Athens General Hospital between January 1, 2014 and August 31, 2016 were retrospectively reviewed...
January 19, 2018: Oncology Research
https://www.readbyqxmd.com/read/26564456/-roles-of-tumor-infiltrating-lymphocytes-in-non-small-cell-lung-cancer-recurrence-and-metastasis-a-meta-analysis
#3
Xiang Yan, Shun-chang Jiao
OBJECTIVE: To determine the prognostic value of tumor-infiltrating lymphocytes in the recurrence and metastasis of non-small cell lung cancer (NSCLC). METHODS: A PubMed, EMBASE, Cochrane Library databases, NIH databases, and China Biology Medicine disc, China National Knowledge Infrastructure, Chinese Science and Technology Periodical literature search strategy was designed. Studies on the prognostic values of intratumoural CD3⁺,CD4⁺,CD8⁺, and FoxP3+lymphocytes for NSLCL were retrieved...
August 2015: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
https://www.readbyqxmd.com/read/26379973/cytotoxic-t-lymphocyte-associated-antigen-4-49a-g-polymorphism-and-the-risk-of-non-small-cell-lung-cancer-in-a-chinese-population
#4
Hui-Ning Liu, Jian-Ling Su, Shao-Hui Zhou, Li-Jun Liu, Peng Qie
BACKGROUND: CTLA-4 is a potent immunoregulatory molecule and plays a pivotal role in the negative regulation of T-cell proliferation and activation. Previously, the association between CTLA-4 +49A>G polymorphism and the risk of NSCLC has been investigated in several studies, however, their results were inconsistent. Therefore, we aimed to investigated the association between CTLA-4 +49A>G polymorphism and the risk of NSCLC in a Chinese population. METHODS: We recruited 231 NSCLC patients and 250 healthy controls in the present case-control study...
2015: International Journal of Clinical and Experimental Medicine
https://www.readbyqxmd.com/read/25481662/how-do-elderly-poor-prognosis-patients-tolerate-palliative-concurrent-chemoradiotherapy-for-locally-advanced-non-small-cell-lung-cancer-stage-iii-a-subset-analysis-from-a-clinical-phase-iii-trial
#5
MULTICENTER STUDY
Hans H Strøm, Roy M Bremnes, Stein H Sundstrøm, Nina Helbekkmo, Ulf Aasebø
BACKGROUND: In a phase III trial of patients with unresectable, locally advanced, stage III non-small-cell lung cancer (NSCLC) with a poor prognosis, palliative concurrent chemoradiotherapy (CRT) provided a significantly better outcome than chemotherapy alone, except among performance status (PS) 2 patients. In the present subgroup analysis, we evaluated the effect on patients aged ≥ 70 years (42% of all included) compared with patients aged < 70 years enrolled in the trial. PATIENTS AND METHODS: All patients received 4 courses of intravenous carboplatin and oral vinorelbine...
May 2015: Clinical Lung Cancer
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"